See what questions
a doctor would ask.
Phenoxodiol has proved in clinical trials that it is capable of slowing hormone-refractory prostate cancer growth (metastatic stage of cancer with survival rate of 1 to 2 years). It is anticipated that the drug may be used as first option chemotherapy and second option chemotherapy for patients who fail to respond to docetaxel. In the small clinical trial, results showed that disease progression delay reflected phonoxodiol dosage – the higher the dose, the longer it took for the cancer to progress. The drug was found to be well tolerated with o obvious side effects. A large scale trial is expected to follow. The drug has not yet had FDA approval. Another recently approved treatment involving a combination of docetaxel and prednisone increases survival time on average by only 10 weeks.
Source: summary of medical news story as reported by PR Newswire
About: Small clinical trial of phenoxodiol shows it may be very effective in improving survival of prostate cancer patients
Date: 22 November 2004
Source: PR Newswire
http:/ This summary article refers to the following medical categories:
Related Medical Topics
More News Topics
This summary article refers to the following medical categories:
Search Specialists by State and City